Citadel Advisors
CBMG

Citadel Advisors’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Citadel Advisors’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,368
Closed -$188K – 10070
2018
Q3 		$188K Buy
+10,368
New +$213K ﹤0.01% 8254

Other funds holding CBMG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citadel Advisors's CBMG Position: Q4 2018 in Review

Citadel Advisors sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q4 2018, closing a stake of 10,368 shares — an estimated $188K sold.

Citadel Advisors first reported a position in CBMG in Q3 2018 and held it in 1 quarter. The position peaked at $188K in Q3 2018. 35 funds tracked by Wall St. Rank hold CBMG as of Q4 2018.

  • Citadel Advisors reported no remaining Cellular Biomedicine Group, Inc. position as of Q4 2018 after selling out during the quarter.
  • Citadel Advisors sold 10,368 Cellular Biomedicine Group, Inc. shares in Q4 2018, an estimated $188K.
  • Citadel Advisors first reported a position in Cellular Biomedicine Group, Inc. in Q3 2018 and held it in 1 quarter.
  • Citadel Advisors's Cellular Biomedicine Group, Inc. position peaked at $188K in Q3 2018.
  • 35 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q4 2018.

Based on Citadel Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.